.Ziyang Li

Dr. .Ziyang Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Hepatology Communications
Verified
Journal Article
Open access
QLQichen Long
Qichen Long
FLFengming Luo
Fengming Luo
BLBinghui Li
Binghui Li
.L.Ziyang Li
.Ziyang Li
ZGZhe Guo
Zhe Guo
MHmin Hu
min Hu
Metabolic dysfunction–associated steatotic liver disease (MASLD), a replacement of the nomenclature employed for NAFLD, is the most prevalent chronic liver disease worldwide. Despite its high global prevalence, NAFLD is often under-recognized due to the absence of reliable noninvasive biomarkers for diagnosis and staging. Growing evidence suggests that the gut microbiome plays a significant role in the occurrence and progression of NAFLD by causing immune dysregulation and metabolic alterations due to gut dysbiosis. The rapid advancement of sequencing tools and metabolomics has enabled the identification of alterations in microbiome signatures and gut microbiota-derived metabolite profiles in numerous clinical studies related to NAFLD. Overall, these studies have shown a decrease in α-diversity and changes in gut microbiota abundance, characterized by increased levels of Escherichia and Prevotella, and decreased levels of Akkermansia muciniphila and Faecalibacterium in patients with NAFLD. Furthermore, bile acids, short-chain fatty acids, trimethylamine N-oxide, and tryptophan metabolites are believed to be closely associated with the onset and progression of NAFLD. In this review, we provide novel insights into the vital role of gut microbiome in the pathogenesis of NAFLD. Specifically, we summarize the major classes of gut microbiota and metabolic biomarkers in NAFLD, thereby highlighting the links between specific bacterial species and certain gut microbiota-derived metabolites in patients with NAFLD.

27 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LYLang Yi
Lang Yi
LTLi Tan
Li Tan
QLQichen Long
Qichen Long
XLXing Lyu
Xing Lyu
HZHuihui Zeng
Huihui Zeng
MHmin Hu
min Hu
Lower respiratory tract infections are characterized by high morbidity and mortality, the latter associated with the low sensitivity and long turnaround time (TAT) of traditional diagnostic methods. Advances in next-generation sequencing (NGS) offers a promising solution, but in the face of so many different NGS products, how to use them appropriately remains a great challenge for clinicians. This study included 205 patients with suspected lower respiratory tract infections from the department of respiratory and critical care medicine, and collected their lower respiratory tract samples for metagenomic NGS (mNGS) and two different targeted NGS (tNGS), amplification-based tNGS and capture-based tNGS. We analyzed their microorganisms reported, and evaluated their detection performance based on the comprehensive clinical diagnosis. Compared to the two tNGS, mNGS showed significant higher cost ($840) and longer TAT (20 h). Conversely, it identified the highest number of species, totaling 80, compared to 71 species identified by capture-based tNGS and 65 species by amplification-based tNGS. When benchmarked against the comprehensive clinical diagnosis, the capture-based tNGS demonstrated significantly higher diagnostic performance than the other two NGS, with an accuracy of 93.17% and a sensitivity of 99.43%. However, it showed lower specificity compared to the amplification-based tNGS in identifying DNA virus (74.78% vs. 98.25%). The amplification-based tNGS exhibited a poor sensitivity for both gram-positive (40.23%) and gram-negative bacteria (71.74%). Moreover, tNGS was able to identify genotypes, antimicrobial resistance genes and virulence factors. In conclusion, mNGS is suited for the detection of rare pathogens; the capture-based tNGS is preferable for routine diagnostic testing; the amplification-based tNGS can be an alternative in situations requiring rapid results and constrained by limited resources.

26 May 2025 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
ZCZhiyang Chen
Zhiyang Chen
XLXin Liu
Xin Liu
LTLi Tan
Li Tan
XLXing Lyu
Xing Lyu
QLQichen Long
Qichen Long
MHmin Hu
min Hu
Objectives: This study aims to compare the diagnostic efficiency and consistency of metagenomic next-generation sequencing (mNGS) and targeted next-generation sequencing (tNGS) in patients with lower respiratory tract fungal infections.Methods: A total of 115 patients with probable pulmonary infection between September 2022 and April 2023 were enrolled at the Second Xiangya Hospital, Changsha, China, of which 61 were clinically diagnosed with invasive pulmonary fungal infection (IPFI) and 54 were non-IPFI cases. All patients received bronchoalveolar lavage, with mNGS, tNGS, and cultures being conducted paralleled. Diagnostic effectiveness and consistency in detecting microorganisms were compared.Results: Both mNGS and tNGS showed high sensitivity rates of 95.08% each, with specificity of 90.74% and 85.19%, respectively. They also demonstrated positive predictive values (PPVs) of 92.1% and 87.9% and negative predictive values (NPVs) of 94.2% and 93.9%, respectively, in diagnosing IPFI. The sensitivity and NPV of mNGS and tNGS were superior to that of any individual or combined conventional microbiological tests (CMTs) (P < 0.05). The consistency of culture with mNGS and tNGS was 48.70% and 50.43%, respectively. For fungal detection, Pneumocystis jirovecii (26/61, 42.6%; and 28/61, 45.9%), Candida albicans (19/61, 31.1%; and 21/61, 34.4%), and Aspergillus fumigatus (16/61, 26.2%; and 15/61, 24.6%) are most prevalent for mNGS and tNGS in enrolled cases, and the detection rate was greatly higher than that of culture. Furthermore, mNGS and tNGS were capable of diagnosing mixed infections in 65 and 55 out of the 115 cases, whereas only nine cases of bacterial-fungal infection were detected by culture.Conclusion: The diagnostic efficacy of mNGS and tNGS was comparable to that of identified IPFI. NGS-based methodologies present a promising tool for detecting IPFI, which can be a good supplement to CMT.


9 April 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PLPeiting Liu
Peiting Liu
JZJialiang Zhang
Jialiang Zhang
XLXin Liu
Xin Liu
BLBinghui Li
Binghui Li
YPYingqian Peng
Yingqian Peng
MHmin Hu
min Hu

29 April 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
BLBinghui Li
Binghui Li
YZYiru Zhang
Yiru Zhang
.L.Ziyang Li
.Ziyang Li
ZCZhiyang Chen
Zhiyang Chen
ZGZhe Guo
Zhe Guo
QLQichen Long
Qichen Long
Metabolic dysfunction-associated steatotic liver disease (MASLD) presents a growing global health burden, while reliable non-invasive biomarkers for identi